



## ImmunoGen Appoints Stacy Coen as Senior Vice President and Chief Business Officer

June 1, 2020

WALTHAM, Mass.--(BUSINESS WIRE)--Jun. 1, 2020-- [ImmunoGen, Inc.](#) (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Stacy A. Coen has been appointed Senior Vice President and Chief Business Officer.

"We are excited to welcome Stacy to the ImmunoGen leadership team as mirvetuximab soravtansine moves through registration studies and our early-stage pipeline continues to advance," said Mark Enyedy, ImmunoGen's President and Chief Executive Officer. "Stacy is a proven business leader with broad corporate strategy and business development expertise, and will play an important role in our organization as we continue to execute against our strategy, explore new opportunities for our pipeline, and seek to bring mirvetuximab to patients as quickly as possible."

Ms. Coen brings over 20 years of business and corporate development experience from leading oncology and rare disease companies. She joins ImmunoGen from Editas Medicine, where she served as Vice President, Business Development and was responsible for business development, strategy, transactions, and alliance management. Prior to joining Editas, Ms. Coen served in multiple roles of increasing responsibility at Genzyme Corporation (now known as Sanofi Genzyme), including Vice President, Head of Rare Disease Business Development and Licensing, and Vice President, Global Head of Strategy and Business Development, Multiple Sclerosis, among others. She currently serves on the Board of Trustees of Huntington's Disease Society of America and is a member of MassBio and the Alliance for Regenerative Medicine (ARM). Ms. Coen received a BS in Finance and Economics from the University of Massachusetts and an MBA from the Darden Graduate School of Business at the University of Virginia.

"I am delighted to join ImmunoGen as the Company works to bring its first product to market and advance a portfolio of novel ADCs," said Ms. Coen. "I look forward to working with the talented team at ImmunoGen and contributing to the goal of delivering more good days to people living with cancer."

### ABOUT IMMUNOGEN

ImmunoGen is developing the next generation of antibody-drug conjugates to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to "target a better now."

Learn more about who we are, what we do, and how we do it at [www.immunogen.com](http://www.immunogen.com).

### FORWARD LOOKING STATEMENTS

This press release includes forward-looking statements based on management's current expectations. These statements include, but are not limited to, ImmunoGen's expectations related to the advancement of ImmunoGen's research and development programs and Ms. Coen's potential contributions to ImmunoGen. For these statements, ImmunoGen claims the protection of the safe harbor for forward-looking statements provided by the Private Securities Litigation Reform Act of 1995. Various factors could cause ImmunoGen's actual results to differ materially from those discussed or implied in the forward-looking statements, and you are cautioned not to place undue reliance on these forward-looking statements, which are current only as of the date of this release. Factors that could cause future results to differ materially from such expectations include, but are not limited to: the timing and outcome of ImmunoGen's pre-clinical and clinical development processes; the difficulties inherent in the development of novel pharmaceuticals, including uncertainties as to the timing, expense, and results of pre-clinical studies, clinical trials, and regulatory processes; ImmunoGen's ability to financially support its product programs; risks and uncertainties associated with the scale and duration of the COVID-19 pandemic and resulting impact on ImmunoGen's industry and business; and other factors more fully described in ImmunoGen's Annual Report on Form 10-K for the year ended December 31, 2019 and other reports filed with the Securities and Exchange Commission.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20200601005090/en/): <https://www.businesswire.com/news/home/20200601005090/en/>

### INVESTOR RELATIONS AND MEDIA

ImmunoGen  
Courtney O'Konek  
781-895-0600  
[courtney.okonek@immunogen.com](mailto:courtney.okonek@immunogen.com)

OR

FTI Consulting  
Robert Stanislaro  
212-850-5657  
[robert.stanislaro@fticonsulting.com](mailto:robert.stanislaro@fticonsulting.com)

Source: ImmunoGen, Inc.